AWM
VKTX icon

Abound Wealth Management’s Viking Therapeutics VKTX Stock Holding History

Abound Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6
Closed -$196 – 1577
2026
Q1 		$196 Buy
+6
New +$193 ﹤0.01% 1248

Other funds holding VKTX

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
RFM
Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Abound Wealth Management's VKTX Position: Q2 2026 in Review

Abound Wealth Management sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 6 shares — an estimated $196 sold.

Abound Wealth Management first reported a position in VKTX in Q1 2026 and held it in 1 quarter. The position peaked at $196 in Q1 2026. 47 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Abound Wealth Management reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Abound Wealth Management sold 6 Viking Therapeutics shares in Q2 2026, an estimated $196.
  • Abound Wealth Management first reported a position in Viking Therapeutics in Q1 2026 and held it in 1 quarter.
  • Abound Wealth Management's Viking Therapeutics position peaked at $196 in Q1 2026.
  • 47 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.